Table 2.
Biomarker | Univariate | Multivariate* | ||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Survivin and Ki-67 as continuous | ||||
B7-H1 | ||||
Negative | 1.0 (reference) | 1.0 (reference) | ||
Positive | 3.98 (2.96–5.33) | <.001 | 1.97 (1.41–2.75) | <.001 |
Survivin, 5-unit increase | 1.17 (1.15–1.20) | <.001 | 1.11 (1.08–1.14) | <.001 |
Ki-67, 5-unit increase | 1.04 (1.03–1.05) | <.001 | 1.02 (1.02–1.03) | <.001 |
Survivin and Ki-67 as quartiles | ||||
B7-H1 | ||||
Negative | 1.0 (reference) | 1.0 (reference) | ||
Positive | 3.98 (2.96–5.33) | <.001 | 2.14 (1.54–2.96) | <.001 |
Survivin | ||||
1st quartile, 0–2.9 | 1.0 (reference) | 1.0 (reference) | ||
2nd quartile, 3.0–7.9 | 1.40 (0.84–2.33) | .193 | 1.19 (0.71–1.99) | .517 |
3rd quartile, 8.0–19.9 | 1.92 (1.16–3.18) | .011 | 1.28 (0.75–2.20) | .360 |
4th quartile, ≥20 | 6.74 (4.28–10.64) | <.001 | 2.85 (1.66–4.87) | <.001 |
Ki-67 | ||||
1st quartile, 0–14.9 | 1.0 (reference) | 1.0 (reference) | ||
2nd quartile, 15.0–34.9 | 1.62 (0.94–2.78) | .080 | 1.50 (0.86–2.62) | .152 |
3rd quartile, 35.0–74.9 | 2.34 (1.41–3.90) | .001 | 1.81 (1.06–3.09) | .031 |
4th quartile, ≥75 | 6.36 (3.98–10.19) | <.001 | 3.17 (1.85–5.43) | <.001 |
Survivin and Ki-67 as dichotomous | ||||
B7-H1 | ||||
Negative | 1.0 (reference) | 1.0 (reference) | ||
Positive | 3.98 (2.96–5.33) | <.001 | 2.16 (1.57–2.96) | <.001 |
Survivin | ||||
Low, <15 | 1.0 (reference) | 1.0 (reference) | ||
High, ≥15 | 4.56 (3.46–6.00) | <.001 | 2.76 (2.00–3.80) | <.001 |
Ki-67 | ||||
Low, <50 | 1.0 (reference) | 1.0 (reference) | ||
High, ≥50 | 3.42 (2.59–4.52) | <.001 | 1.95 (1.42–2.67) | <.001 |
RCC indicates renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval.
Multivariate HRs for each biomarker were adjusted for the effects of the remaining 2.